Aslam, R.; Richards, C.E.; Fay, J.; Hudson, L.; Workman, J.; Lee, C.L.; Murphy, A.; O’Neill, B.; Toomey, S.; Hennessy, B.T.
Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. Int. J. Mol. Sci. 2024, 25, 13264.
https://doi.org/10.3390/ijms252413264
AMA Style
Aslam R, Richards CE, Fay J, Hudson L, Workman J, Lee CL, Murphy A, O’Neill B, Toomey S, Hennessy BT.
Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences. 2024; 25(24):13264.
https://doi.org/10.3390/ijms252413264
Chicago/Turabian Style
Aslam, Razia, Cathy E. Richards, Joanna Fay, Lance Hudson, Julie Workman, Cha Len Lee, Adrian Murphy, Brian O’Neill, Sinead Toomey, and Bryan T. Hennessy.
2024. "Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models" International Journal of Molecular Sciences 25, no. 24: 13264.
https://doi.org/10.3390/ijms252413264
APA Style
Aslam, R., Richards, C. E., Fay, J., Hudson, L., Workman, J., Lee, C. L., Murphy, A., O’Neill, B., Toomey, S., & Hennessy, B. T.
(2024). Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences, 25(24), 13264.
https://doi.org/10.3390/ijms252413264
